Skip to main content
DNA Research: An International Journal for Rapid Publication of Reports on Genes and Genomes logoLink to DNA Research: An International Journal for Rapid Publication of Reports on Genes and Genomes
. 2007 May 23;14(2):79–89. doi: 10.1093/dnares/dsm007

Merging Mouse Transcriptome Analyses with Parkinson's Disease Linkage Studies

Daniel Gherbassi 1, Lavinia Bhatt 1, Sandrine Thuret 1,, Horst H Simon 1,*
PMCID: PMC2779897  PMID: 17522092

Abstract

The hallmark of Parkinson's disease (PD OMIM #168600) is the degeneration of the nigral dopaminergic system affecting approximately 1% of the human population older than 65. In pursuit of genetic factors contributing to PD, linkage and association studies identified several susceptibility genes. The majority of these genes are expressed by the dopamine-producing neurons in the substantia nigra. We, therefore, propose expression by these neurons as a selection criterion, to narrow down, in a rational manner, the number of candidate genes in orphan PD loci, where no mutation has been associated thus far. We determined the corresponding human chromosome locations of 1435 murine cDNA fragments obtained from murine expression analyses of nigral dopaminergic neurons and combined these data with human linkage studies. These fragments represent 19 genes within orphan OMIM PD loci. We used the same approach for independent association studies and determined the genes in neighborhood to the peaks with the highest LOD score value. Our approach did not make any assumptions about disease mechanisms, but it, nevertheless, revealed α-synuclein, NR4A2 (Nurr1), and the tau genes, which had previously been associated to PD. Furthermore, our transcriptome analysis identified several classes of candidate genes for PD mutations and may also provide insight into the molecular pathways active in nigral dopaminergic neurons.

Key words: dopaminergic neurons, substantia nigra, neurodegenerative disease, candidate genes

1. Introduction

The neuropathological hallmark of Parkinson's disease (PD) is the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), affecting about 1–2% of the human population older than 65 years.1 It is characterized by the clinical symptoms of resting tremor, muscular rigidity, postural instability, a positive response to the administration of l-DOPA, and the presence of cytoplasmic inclusions in postmortem brains, Lewy Bodies.2 Despite its mostly sporadic onset and a high discordance rate in monozygotic twins,3 several human linkage studies had been initiated to determine susceptibility genes for this disease.4 In the Online Mendelian Inheritance in Man (OMIM) database, 13 PD loci have been recorded: PARK1,5 PARK2,69 PARK3,10 PARK4,11,12 PARK5,13 PARK6,14,15 PARK7,16,17 PARK8,18 PARK9,19,20 PARK10,21 PARK11,22,23 PaRK12,23,24 and PARK13.25 Furthermore, genome-wide analyses of multiplex PD families provided evidence for linkage to regions on different chromosomes.21,22,24,2629 The PARK loci are sometimes larger than 10 Mb and can contain hundreds of genes. In case of the genome-wide linkage studies for a complex, multifactorial disease such as PD, the regions with high LOD scores are rarely smaller than 20 cM.29 The differences among independent studies and the size of the suggested susceptibility regions make the searches for the underlying mutations irremediably a time-consuming process.

For several PARK loci, the searches have been successful. Mutations in α-synuclein (PARK1 and PARK4), DJ-1 (PARK7), parkin (PARK2), PINK1 (PTEN-induced putative kinase) (PARK6), LRRK2 (leucine-rich repeat kinase 2) (PARK8), UCHL1 (ubiquitin carboxy-terminal-hydrolase-L1) (PARK5), and ATP13A2 (ATPase type 13A2) (PARK9) have been identified.5,3037 Other studies have revealed the cytoskeletal protein tau (MAPT)36,38 and the ligand-independent nuclear receptor NR4A230,39,40 (Nurr1) as susceptibility genes. Although the definite role in PD of many of these genes is still discussed and controversial (especially for NR4A2 and UCHL1) and the known mutations account for less than 10% of all PD cases, the investigation into the functions of the underlying genes has generated an insight into the fundamental disease pathogenesis. For example, α-synuclein and parkin turned out to be major protein components of Lewy bodies in sporadic PD.41 Mutations in parkin, UCHL1, and DJ-1 suggest that abnormal protein folding and protein degradation through the ubiquitin-proteasome system is an important factor in the etiology of the disease.42,43 PINK1 may be involved in the phosphorylation of mitochondrial proteins in response to cellular stress, thus protecting against mitochondrial dysfunction.35 Interestingly, mitochondria are also the site, where the known neurotoxins for DA neurons operate, suggesting that their malfunctioning could be a major contributor to PD pathogenesis.44

Current or future searches for the underlying mutations in the remaining orphan Parkinson loci could be accelerated and widened to promoter regions and to haplotype variations, if the number of candidate genes is narrowed down by other criteria. At least seven out of the nine PD-associated genes are expressed by nigral DA neurons,4550 with different expression levels and specificity. These are α-synuclein, NR4A2, parkin,46 PINK1, tau, UCHL1, and LRRK1 (http://www.brain-map.org). For this reason, we propose expression (specific or non-specific) by mesDA neurons as a selection criterion to identify candidate genes in those PD loci where the underlying gene is still unknown (orphan). Such an approach does not make any presumption with respect to disease mechanisms. Conceptually, the same method was applied on five large PD loci using serial analysis of gene expression for a comparative expression analysis of SNpc and adjacent mesencephalon in postmortem brains.51 As cell-specific expression in mouse and human is very similar, we took three murine expression studies which employed fluorescent-activated cell sorting (FACS) and two unrelated subtractive methods for the identification of genes expressed by mesDA neurons.5254 We collected the cDNA sequences of these expression analyses from public databases, determined the underlying genes and the corresponding gene ontology annotations [Gene Ontology (GO)] to obtain insight into their function. Then, we established their genetic locations and their syntenic positions on the human genome. Finally, we combined these data with existing human PD linkage studies.511,1324,2629,55,56

2. Material and methods

2.1. Transcriptome analysis

All nucleotide sequences used in this study are publicly available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide and derived from three expression analyses in mouse: (i) Barrett et al.52 published 779 sequences (Accession Nos.: BE824469–BE824504, BE824506–BE824519, BE824521–BE824561, BE824563–BE824823, BE824825–BE825045, BE825047–BE825132, CK338036–CK338155). (ii) Stewart et al.53,57,58 published 496 cDNA sequences (Accession Nos.: AA008736, W33210–W33212, W33214–W33289, W35421–W35480, W36130–W36269, W39787–W40005, W40007–W40008, W40010–W40023, W45732). (iii) We published 160 sequences (Accession Nos.: CO436137–CO436293).54

Each nucleotide sequence was employed for a nucleotide-nucleotide BLAST (blastn) (basic local alignment search tool) on the nr database (non-redundant) (http://www.ncbi.nlm.nih.gov/BLAST/) and on the mouse genome (http://www.ncbi.nlm.nih.gov/genome/seq/MmBlast.html). We then recorded those alignments with the highest scores, the lowest e-values, and highest number of hits in a single locus. BLAST results were categorized into four groups: (1) no significant alignments on mouse genome (None), (2) significant alignments with mitochondrial DNA (Mitochondrial Genes), (3) multiple high-scoring alignments on mouse genome (Multiple Hits) for ambiguous results, and (4) significant alignments on mouse genome for single hits or otherwise unambiguous results (Table 1). The latter group was further subdivided into: ‘Genes’, ‘ESTs’, and ‘genomic Sequences’. The group ‘Genes’ comprises the results with high-scoring alignments in exons of single genes. In some cases, where the alignment lay in the region after the last exon or, according to the chromosome map view, in an intron of a given gene, we termed it also ‘Gene’, if the hit was in a UniGene cluster which was linked to the gene in the locus. With those alignments that we were unable to associate to a gene, we performed a blastn on the MmEST database. If we could associate the sequence to a previously described EST, we termed it ‘EST’; otherwise, it was termed ‘Genomic Sequence’.

Table 1.

BLAST results on mouse genome

No significant alignments on mouse genome 262 None
Significant alignments with mitochondrial genes 104 Mitochondrial genes
Multiple high-scoring alignments on mouse genome 19 Multiple hits
Significant alignments on mouse genome 1050 Genes (940)
Annotated genes (793)
Hypothetical genes (147)
ESTs (47)
Genomic sequences (63)

cDNA sequences are separated into four different categories based on the types of alignments generated. Alignments on the mouse genome were subdivided into Genes, ESTs, and genomic sequences. For the category ‘Genes’, we differentiated further between ‘annotated’ and ‘hypothetical’ depending on the gene RefSeq status recorded at NCBI.72

For all the ‘Annotated Genes’, ‘Hypothetical Genes’, and mitochondrial genes, the following data were collected from the locus link feature (http://www.ncbi.nlm.nih.gov/LocusLink this was replaced by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene during the course of this study): the gene name, gene symbol, accession number, Gene ID, and the MGI link number, if available. The latter provides a relational link to the GO library and the information related to ‘biological processes’, ‘cellular components’, and ‘molecular functions’.

For all cDNA sequences categorized by ‘Significant Alignments on Mouse Genome’, we also registered the exact chromosomal position in kilobases (starting from the top of the short arm).

2.2. Mapping the murine cDNA sequences to the human genome

For most of the murine genes, a human homolog has already been determined, normally carrying the same name and symbol. This information is registered on the Entrez Gene page together with the cytogenetic locations. When this information did not exist, we used the mouse protein sequence of the identified gene for a translated BLAST (tblastn), or the nucleotide sequence of the cDNA fragment or the GenBank accession number of the corresponding gene for a blastn on the human genome. We registered the position in kilobases on the chromosome and verified each position on the human genome by comparing the neighboring genes to those in the mouse genome and recorded the human position only if the neighboring genes also matched.

When the cytogenetic position on the human genome was determined, we compared this information with the positions of the recorded PARK loci. We aligned the human chromosome map view with the map for ‘morbid/disease’, described in OMIM (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM). When the genes, or the estimated human locations, and the cytogenetic disease locations co-localized, we called the gene a PD candidate gene. For the loci suggested by genome-wide studies, we selected those genes, which were situated ± 3 Mb from the chromosome marker (single nucleotide polymorphism (SNP)) with the highest LOD score (Table. 5). We are aware that this approach reduces the numbers of genes in an arbitrary manner. However, if preferred, the range can be widened with the provided data (see Supplementary Data) in order to more accurately consider asymmetry or size of each specific linkage peak.

Table 5.

Association studies not recorded at OMIM

Cytogenetic location Genetic marker Mb CM Marshfield LOD score
Bertoli-Avella (03)27 19p13.13 D19S221 12.6 36 2.26
19p13.13 D19S840 13.7 38
DeStefano (01)28 9q34.11 D9S1825 123.3 136 1.3
10q22.1 GATA121A08 70.2 88 1.07
DeStefano (02)56 9q32 D9S930 110.6 120 1.86
20q11.2 D20S478 37.9 54 1.82
21q21 D21S2052 27.7 24 2.21
Hicks (02)55 5q23.3 D5S666 120–137 135 1.6
Li (02)21 10q25.3 D10S1237 116.1 134 2.62
6p21.1 D6S1017 41.7 63 1.88
5q15 D5S1462 96.4 105
5q21.1 Peak 100 108 1.65
5q21.3 D5S1453 105–109 115
17p13.1 D17S1303 10.8 24 1.93
Martinez (04)29 2p12–q22 D2S2216 88 111 1.24
2p11–q12 Peak 102 117 2.04
2q12 D2S160 107 123 1.77
5q23 D5S471 117.5 130 1.05
6p12 D6S257 56 80 1.37
6q11–q13 Peak 69–73 85 1.41
6q14 D6S460 ∼82 90 1.14
7p22 D7S531 3 5 1.51
11q14 D11S4175 89.9 91 1.6
19q13.3 D19S902 53.6 73 1.05
Pankratz (03)24 Xq22.3 DXS8055 113.4 71 3.1
10q11.2 D10S196 51.5 70.0 2.3
Scott (01)26 5q31.1 D5S816 135.4 139 2.39
17p11.2 D17S921 14.5 36 1.92
Two-point and multipoint LOD 17q11.2 D17S1293 32.7 56 2.28
17p11.2 D17S921 14.5 36 2.02
17q11.2 D17S1293 32.7 56 2.62
9q33.1 −10 cM 117.8 130
Multipoint LOD 9q33.3 D9S301 66 cM 126.3 140 2.59
9q34.2 +10 cM 132.3 150
3q13.32 D3S2460 118.7 135 1.62

For each individual study, the highest LOD scores with the associated genetic markers are listed. In these studies, the peak positions and the flanking genetic markers were given in centiMorgan on the Marshfield genetic map. We determined, when possible, the exact position in Mb on the corresponding chromosome. The average distance between the two adjacent genetic markers in each study varied between 5 and 11 cM.

The entire data set was collected and processed using the database program, Filemaker Pro 7.0. The latest update was in February 2007. This database is available upon request.

3. Results

We obtained 1435 sequences from three independent studies, which had the original aim to identify genes expressed by mesDA neurons. Barrett et al.52 had isolated DA neurons from E13 ventral midbrain by FACS. This library contains genes expressed by mesDA neurons with a preference for abundant genes. The other two studies used subtractive methods to enrich for rare RNA transcripts expressed by mesDA neurons. Stewart et al.53,57,58 had created a single-stranded directional cDNA library from substantia nigra of 8-week-old mice subtracted with a cDNA library from cerebellum. We had used a PCR-based differential display method54 employing cDNA from engrailed-1/2 double-mutant and wild-type ventral midbrain during the embryonic stages when mesDA neurons disappear in the mutants.59,60 The amplified sequences were compared to the expression profile of adult olfactory bulb, a source of DA neurons unrelated to those in the ventral midbrain. Only differentially expressed cDNA fragments were isolated and sequenced. As the original sequence analyses of the former two studies had been performed when a smaller nucleotide data set was available and in order to update our own expression analysis, we subjected the sequence data from all three screens to new BLAST searches and determined their association to genes and published ESTs, and their location on the mouse genome. The 1435 cDNA fragments generated 1050 unambiguous murine genomic hits, 19 ambiguous multiple hits, and 104 alignments with mitochondrial DNA. Two hundred and sixty-two cDNA sequences produced no significant alignments (see Table 1 for definitions and the entire analysis, and Table 2 for the individual libraries).

Table 2.

Classification of BLAST results from each library

Total analysis Barrett52 Stewart53 Thuret54
A. Number of unique alignments per individual library
Genesa 423 150 218 77
Hyp. genesb 80 23 39 19
ESTsc 32 16 12 3
Genomic 44 15 8 21
Mitochondria 11 8 2 2
Multiple hitsd 14 6 4 4
Nonee 185 67 111 8
Totalf 789 285 394 134
B. Total number of fragmentsg
Genesa 793 403 293 97
Hyp. genesb 147 71 55 21
ESTsc 46 28 15 5
Genomic 62 30 11 21
Mitochondria 104 100 2 2
Multiple hitsd 19 9 4 6
Nonee 262 138 116 8
Total 1435 779 496 160

aAnnotated mouse genes.

bHypothetical genes determined by EST clustering or predicted by automated computational genome analysis with a large open reading frame.

cExpressed sequencing tags.

dUnderlying gene not identifiable, due to multiple alignments with low e-values.

eNo hit in mouse and human genome.

fNumber of unique alignments. Five hundred and seventy-nine unique tags were on the mouse genome (excluding mitochondria).

gNumber of fragments that represent genes, hypothetical genes, ESTs, genomic sequences, multiple alignments, and mitochondrial genes, listed per individual library.

Out of 1050 cDNA fragments, which generated unambiguous alignments on the mouse genome, 1020 were in gene loci. Most of them aligned to exons of those genes (72.6%; 741 of 1020). Out these 1020 cDNA fragments, 181 (17.8%) lay 3′ to the last annotated exon, suggesting that substantial amounts of mRNAs isolated from brain tissue are longer at their 3′ end than mRNAs from other tissues (Table 3). Finally, 9.6% (98 of 1020) of the alignments lay in regions designated as introns, suggesting that they are parts of unrecorded splice variants, possibly specific for mesDA neurons.

Table 3.

Alignments in relation to gene loci

Total Genomic sequences ESTs Genes
In gene loci Only in last exon 471 471
In last and other exon(s) 132 132a
Not in last exon 138 138
After 3′ end 181 6 16 159
Intron 98 40 10 48
Subtotal 1020 46 26 948
Outside gene loci 30 17 13
Total 1050 63 39 948

Genomic alignments were divided into three groups: ‘ESTs’ (3.7%), ‘genomic sequences’ (6.0%), and ‘genes’ (90.3%). Majority of the cDNA fragments that aligned with genes are aligned with the last exon. A significant number of the cDNAs aligned with the region 3′ to the last exon. See Material and Methods for details.

aForty-four hits are in genes with only one exon.

The 1050 cDNA fragments represented 503 genes (423 annotated and 80 hypothetical genes), 32 ESTs, and 44 unique genomic hits with no otherwise described ESTs. Additionally, the 104 sequences that aligned to the mitochondrial DNA represented 11 mitochondrial genes (Table 2). To these cDNA sequences, we associated the corresponding MGI numbers, if available. This provided us with insight into their molecular function, the cellular locations of the proteins, and the associated biological process (see Supplementary Data for the entire transcriptome analysis). Several protein classes were over-represented, like, for example, those, which take part in mitochondria-related processes, in fatty acid chain metabolism, in ubiquitination, in the MAPK signaling pathways, or which are chaperones. Some of these molecular pathways were previously linked to the death of mesDA neurons, to PD, and other human neurodegenerative disorders.

The majority of the mutations, which are associated to PD, is in genes that are expressed in mesDA neurons. We, therefore, joined these expression analyses with human PD linkage and association studies,511,1324,2629,55,56 where no mutation has been associated thus far. For each unique mouse cDNA sequencing tag, we determined its human homolog and the corresponding cytogenetic and physical positions on the human chromosomes. We verified each locus on the human genome by identifying the neighboring genes on the mouse genome and recorded the human position only if the adjacent genes were the same. We then determined whether these positions were within OMIM (Table 4) and other suggestive (non-OMIM) PD loci (Table 5). In case of the OMIM orphan PD loci, we projected on the human chromosome view the map for ‘morbid diseases’. In case of non-OMIM loci, we identified the genes ± 3 Mb to the SNP marker with the highest LOD score. Totally, we linked the mouse transcriptome analyses to 569 unique locations on the human genome. Nineteen of these are within orphan PARK loci (Table 6) and 51 in non-OMIM PD loci (Table 7).

Table 4.

PARK loci

Locus OMIM identifier Gene Cytogenetic location From (kb) To (kb) Mb Number of genes
PARK1 163890 SNCA 4q21.1-4q21.3
PARK2 602544 Parkin 6q25.3-6q26
PARK3 602404 2p13.3-2p13.1 68.075 75.307 7.2 106
PARK4 605543 4p15.33-4p15.1 13.424 37.324 23.9 60
PARK5 191342 UCHL1 4p14
PARK6 605909 PINK1 1p36.33-1p35.1
PARK7 602533 DJ1 1p36.23-1p36.22
PARK8 607060 12q11.2-12q13.13 27.908 55.637 27.7 351
PARK9 606693 ATP13A2 1p36.33-1p36.11
PARK10 606852 1p33-1p32.2 47.651 55.380 7.7 76
PARK11 607688 2q36.1-2q37.3 219.844 243.416 23.6 216
PARK12 300557 Xq21-q25 75.950 129.900 40.0 356
PARK13 610297 2p13.1-2p11.2 75.450 84.130 8.7 39
601828 NR4A2 2q22.1-2q23.3
603779 SNCAIP 5q23.1-q23.3
260540 MAPT 17q21.1

Genomic location of PARK loci as recorded in the OMIM databank. For seven of the PARK loci, the mutated genes were identified. The number of genes is the current GenBank estimation of all annotated and predicted genes in the corresponding PARK locus. For the PARK10 locus, we used the narrow definition 1p33-1p32.2 as determined by the two genetic markers D1S2134 and D1S200, and not the entire shorter arm of chromosome 1 (1p) which contains 1232 genes.21

Table 6.

Candidate genes in Orphan PARK loci

No. of cDNA fragments aligning with the gene Mouse ID Human ID Symbol Human gene name Position Locus
1 NM_146169 XM_376062 KIAA1155 KIAA1155 protein 2p13.3 Park3
1 NM_008717 NM_014497 ZFML Zinc finger, matrin-like 2p13.2–p13.1 Park3
1 NM_183138 XM_371501 MGC22014 cDNA sequence BC037432 2p13.1 Park3
3 NM_080555 NM_003713 PPAP2B Phosphatidic acid phosphatase type 2B 1p32 Park10
1 AA819910 Estimated FAF1 In locus of Fas-associated factor 1 1p33 Park10
6 NM_009129 NM_003469 SCG2 Secretogranin II 2q35–q36 PARK11
3 AK052241 NM_005544 IRS1 Insulin receptor substrate 1 2q36 PARK11
1 NM_152915 NM_139072 DNER Delta/notch-like EGF-related receptor 2q37.1 PARK11
1 NM_008440 NM_004321 KIF1A Kinesin family member 1A 2q37.3 PARK11
2 NM_024197 NM_004544 NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 2q37.3 PARK11
1 NM_025437 NM_001412 EIF1AX Eukaryotic translation initiation factor 1A, X-linked Xp22.13 PARK12
2 NM_019768 NM_012286 MORF4L2 Mortality factor 4 like 2 Xq22 PARK12
3 NM_011123 NM_000533 PLP1 Proteolipid protein 1 Xq22 PARK12
3 NM_013898 NM_004085 TIMM8A Translocase of inner mitochondrial membrane 8 homolog a Xq22.1 PARK12
3 NM_016783 NM_006667 PGRMC1 Progesterone receptor membrane component 1 Xq22–q24 PARK12
7 NM_030688 estimated IL1RAPL2 After 3′ of interleukin 1 receptor accessory protein-like 2 Xq22.2–q22.3 PARK12
1 NM_133196 NM_001325 CSTF2 Cleavage stimulation factor, 3′ pre-RNA, subunit 2 Xq22.1 PARK12
1 NM_025893 NM_173798 ZCCHC12 Zinc finger, CCHC domain containing 12 Xq24 PARK12
2 NM_172782 NM_018698 NXT2 Nuclear transport factor 2-like export factor 2 Xq23 PARK12

Table 7.

Candidate genes for non-OMIM PARK loci

GenBank ID Human ID Symbol Human location In kbb Gene name
Scott (01) D3S246026
5 NM_008083 NM_002045 GAP43 3q13.1–13.2 116700 Growth-associated protein 43
3 BB626331 EST Lsamp 3q13.2–q21 117200 Limbic system-associated membrane protein
2 NM_177093 XM_057296 LRRC58 3q13.33 121300 Leucine-rich repeat containing 58
2 NM_008047 NM_007085 FSTl 3q13.32–q13.3 121460 follistatin-like 1
Martinez (04) D5S47129
1 XM_283496 NM_005509 DMXL1 5q22 118600 Dmx-like 1
1 Genomic Estimated FEM1C 5q22 114939 fem-1 homolog c
3 NM_152809 NM_004384 CSNK1G3 5q23 123000 Casein kinase 1, gamma 3
Li (02) D5S1462 D5S145321
1 NM_172827 EST LNPEP 5q15 96440 Leucyl/cystinyl aminopeptidase
Hicks (02). Scott (01) D5S666. D5S81626,55
1 NM_173753 NM_001008738 FNIP1 5q31.1 131060 Folliculin interacting protein 1
1 NM_144823 NM_015256 ACSL6 5q31 131400 Acyl-CoA synthetase long-chain family member
1 NM_033144 XM_034872 SEPT8 5q31 132180 Septin 8
1 AK011363 NM_003337 UBE2B 5q23–q31 133800 Ubiquitin-conjugating enzyme E2B, RAD6 homology
Scott (01) D5S81626
1 NM_029518 NM_016604 JMJD1B 5q31 137810 Jumonji domain containing 1B
3 NM_010771 NM_018834 MATR3 5q31.3 138730 Matrin 3
Li (02) D6S101721
1 NM_025365 NM_013397 C6ORF49 6p21.31 41800 Chromosome 6 open reading frame 49
1 NM_020493 NM_003131 SRF 6p21.1 43200 Serum response factor (c-fos serum response element-binding transcription factor)
5 NM_008302 NM_007355 HSP90AB1 6p12 44300 Heat shock protein 90 kDa alpha (cytosolic), class B member 1
Martinez (04) D6S257 D6S46029
1 Genomic Estimated 6q12–q13 72500
8 NM_010106 NM_001402 EEF1A1 6q14.1 74224 Eukaryotic translation elongation factor 1 alpha 1
Martinez (04) D7S53129
1 NM_028469 NM_032350 MGC11257 7p22.3 850 Hypothetical protein MGC11257
1 NM_010302 NM_007353 GNA12 7p22–p21 2510 Guanine nucleotide binding protein (G protein) alpha 12 
6 NM_007393 NM_001101 ACTB 7p15–p12 5300 Actin beta
1 NM_026050 NM_032706 MGC12966 7p22.2 6110 Hypothetical protein MGC12966
1 NM_009007 NM_006908 RAC1 7p22 6170 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac)
DeStefano (01) D9S1825,56 Scott (01) D9S30126
7 NM_026434 NM_033117 RBM18 9q34.11 120400 RNA binding motif protein 18
2 NM_022310 NM_005347 HSPA5 9q33–q34.1 123370 Heat shock 70 kD protein 5
1 NM_025709 NM_015635 GAPVD1 9q34.11 123450 GTPase-activating protein and VPS9 domains 1
1 NM_172661 XM_497080 KIAA0515 9q34.1 129650 KIAA0515 gene
DeStefano (01) GATA121A0856
1 NM_183295 NM_015634 KIAA1279 10q22.1 70100 KIAA1279 gene
Martinez (04) D11S417529
1 NM_025844 NM_012124 CHORDC1 11q14.3 89650 Cysteine and histidine-rich domain (CHORD)-containing. zinc-binding protein 1
Li (02) D10S123921
1 NM_172523 NM_003054 VMAT2 10q25 118680 Solute carrier family 18
Li (02) D17S130321
1 NM_018768 NM_004853 STX8 17p12 9350 Syntaxin 8
Scott (01) D17S921, D17S129326
1 NM_011664 NM_018955 UBB 17p12–p11.2 16470 Ubiquitin B
1 NM_011480 NM_004176 SREBF1 17p11.2 17950 Sterol regulatory element binding factor 1
1 XM_110937 NM_145809 USP32 17p11.2 18621 Ubiquitin-specific protease 32
1 NM_026389 NM_015584 POLDIP2 17q11.2 26800 Polymerase delta interacting protein 2
1 NM_174852 NM_020889 PHF12 17q11.1 27400 PHD finger protein 12
1 NM_010897 NM_000267 NF1 17q11.2 29700 Neurofibromatosis 1
1 NM_010161 NM_014210 EVI2A 17q11.2 29800 Ecotropic viral integration site 2A
1 NM_010716 NM_002311 LIG3 17q11.2–q12 33450 Ligase III, DNA, ATP-dependent
Bertoli-Avella (03) D19S22127
2 NM_008319 NM_003259 ICAM5 19p13.2 10260 Intercellular adhesion molecule 5, telencephalin
16 NM_016742 NM_007065 CDC37 19p13.2 10370 Cell division cycle 37 homolog (S. cerevisiae)-like
1 NM_145624 NM_016264 ZNF44 19p13.2 12200 Zinc finger protein 44
1 NM_010906 NM_002501 NFIX 19p13.3 13030 Nuclear factor I/X
1 NM_183097 Estimated 19p13.13 14060 Progestin and adipoQ receptor family member
DeStefano (02) D20S47856
1 BQ927659 Estimated 20q11.2–q12 35330
1 NM_013865 NM_022477 NDRG3 20q11.21–q11.23 36000 n-myc downstream regulated 3
1 NM_010658 NM_005461 MAFB 20q11.2–q13.1 40000 v-maf musculoaponeurotic fibrosarcoma oncogene family. protein B
2 NM_021464 NM_007050 PTPRT 20q12–q13 40500 Protein tyrosine phosphatase. receptor type T
DeStefano (02) D21S205256
2 NM_11782 Estimated ADAMTS5 21q21.2 27170 A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif 5 (aggrecanase-2′) 3′
Pankratz (03) DXS805524
1 NM_016783 NM_006667 PGRMC1 Xq24 116713 Progesterone receptor membrane component 1

Listed genes are situated ± 3 Mb to peak with the highest LOD score, except for D10S196 where we used ± 8Mb.

aNumber of cDNA fragments aligning with the gene.

bkb from the top of the short arm of the chromosome.

cHuman chromosome location was estimated by comparing the flanking regions of mouse and man.

The experimental design of the three different transcriptome analyses, we used for our study, were such that they included both highly and rarely expressed transcripts. Our analysis confirmed the complementary nature of the three screens. Only 7.2% (104 out of 1435) of the cDNA sequences of these libraries represent genes, hypothetical genes, or EST clusters, which are found in more than one of them (Table 8). Moreover, the libraries also contained two cDNA fragments for α-synuclein, three for NR4A2, and one for the tau genes. Mutations in all three genes have been previously associated to PD.5,30,36 Assuming that all 30 000 genes in the human genome61 were equally likely detected, the probability to identify three of nine PD susceptibility genes by chance out of a pool of 569 was less than 3.4 × 10 −3. If we exclude the controversial NR4A2 and UCHL1, the probability was less than 1.5 × 10−2.

Table 8.

cDNA library comparison

Barrett52 Stewart53 Thuret54
Barrett 45 (22) 11 (2)
Stewart 35 (22) 5 (4)
Thuret 3 (2) 5 (4)

Of 1435, 104 (7.2%) cDNA fragments overlap with sequences also present in one other library. This number includes not only fragments that align with each other, but also those which align with the same annotated gene, hypothetical gene, mitochondrial gene, EST, or genomic position. These overlapping 104 cDNA fragments represent 28 of 781 (3.6%) unique tags (Table 2).

4. Discussion

The entire human and mouse genome sequences have been available for more than 3 years.61,62 Therefore, the chromosomal locations of most genes have been determined and as a consequence also those genes within a given disease locus. In order to identify potential PD susceptibility genes, we projected the sequence data of three murine transcriptome studies for mesDA neurons onto the human genome and compared them with previously identified PD loci. We determine the human homologs of 1435 murine cDNA fragments which corresponded to 579 unique mouse chromosomal locations; 423 annotated genes, 80 hypothetical genes, 32 ESTs, and 44 genomic locations, which are not linked to any genes or otherwise reported cDNA sequences. Of the 569 unique locations on the human genome, 19 were positioned in OMIM PARK loci and 51 within genomic regions that have a weaker linkage to PD, which are not recorded in the OMIM database and need further confirmation.

Multiple studies are on the way to determine the underlying mutations of orphan PARK loci63; however, the length of putative regulatory regions of most gene, their unpredictable position, and the common presence of SNPs have thus far restricted such studies to nucleotide variation in the coding region and in 5′ and 3′ UTR. Disparities in the promoter–enhancer–silencer regions were only the aim if the targeted gene had been previously linked to PD.64,65 A nucleotide variation in the α-synuclein promoter, for example, was associated to the disease.12,66 Variability on the level of gene expression is far more common than nucleotide variations which alter protein sequences67 and it is believed that these haplotype variations determine individual traits and predispositions for common diseases such as PD. Narrowing down the number of candidate genes in identified loci in a rational manner may encourage the inclusion of the promoter regions in future studies aiming to identify mutations associated to PD.

Among the candidate genes that we found, the most interesting is VMAT2 (vesicular monoamine transporter 2) (10q25). Reduced expression of VMAT2 could be correlated with a higher sensitivity to environmental factors. For example, VMAT2 heterozygote mice (+/ − ) are remarkably more sensitive than wild-type to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.68,69 Furthermore, we identified two genes in the ubiquitination pathway, Ube2b [ubiquitin-conjugating enzyme E2B, RAD6 homology (S. cerevisiae)] and Ubb (Ubiquitin B, member of the HSP90 family) and Hspa5 (heat shock 70 kDa protein 5, member of the HSP70 family).

Finally, 26 mitochondrial genes encoded by nuclear DNA are present in our transcriptome analysis. Of these, an unexpected high proportion of genes, namely four, are located within orphan OMIM PARK loci. There is increasing evidence that impairment of mitochondrial functions and oxidative stress are contributing factors to PD70 supported by the recent finding of a mutation in PINK1.35 Furthermore, the functional deficiencies induced by several of the other PD mutations seem to converge onto the mitochondria.71 Our finding confirms a central role of the mitochondria in PD and suggests the possibility that a misregulation of some of these four mitochondrial genes may be a contributing factor for the disease.

We conclude that our transcriptome analysis, along with being applicable for the identification of PD candidate genes, may also be a useful tool for future genome-wide association studies with newer resources, such as HapMap (http://www.hapmap.org/), where tagSNPs can be chosen close to loci of genes expressed by mesDA neurons. Furthermore, new GO annotations are constantly added and with time it may turn out that many of the identified genes are part of shared metabolic pathways. Our data set may give new insight into ligand/receptor interactions and/or intracellular signaling pathways acting in mesDA neurons, allowing novel studies into the molecular etiology of PD.

Acknowledgements

This work was supported by a grant from the German Federal Secretary for Education and Research (BMBF) Biofuture 98.

Supplementary Data

Supplementary data are available online at www.dnaresearch.oxfordjournals.org.

References

  • 1.Olanow C. W., Tatton W. G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999;22:123–144. doi: 10.1146/annurev.neuro.22.1.123. [DOI] [PubMed] [Google Scholar]
  • 2.Spillantini M. G., Schmidt M. L., Lee V. M., et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166. [DOI] [PubMed] [Google Scholar]
  • 3.Nussbaum R. L., Polymeropoulos M. H. Genetics of Parkinson's disease. Hum. Mol. Genet. 1997;6:1687–1691. doi: 10.1093/hmg/6.10.1687. [DOI] [PubMed] [Google Scholar]
  • 4.Gasser T. Genetics of Parkinson's disease. J. Neurol. 2001;248:833–840. doi: 10.1007/s004150170066. [DOI] [PubMed] [Google Scholar]
  • 5.Polymeropoulos M. H., Lavedan C., Leroy E., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045–2047. doi: 10.1126/science.276.5321.2045. [DOI] [PubMed] [Google Scholar]
  • 6.Matsumine H., Saito M., Shimoda-Matsubayashi S., et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet. 1997;60:588–596. [PMC free article] [PubMed] [Google Scholar]
  • 7.Tassin J., Durr A., de Broucker T., et al. Chromosome 6-linked autosomal recessive early-onset Parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum, and evidence of a small homozygous deletion in one family. The French Parkinson's Disease Genetics Study Group, and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Am. J. Hum. Genet. 1998;63:88–94. doi: 10.1086/301934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Jones A. C., Yamamura Y., Almasy L., et al. Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am. J. Hum. Genet. 1998;63:80–87. doi: 10.1086/301937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Saito M., Matsumine H., Tanaka H., et al. Refinement of the gene locus for autosomal recessive juvenile parkinsonism (AR-JP) on chromosome 6q25.2-27 and identification of markers exhibiting linkage disequilibrium. J. Hum. Genet. 1998;43:22–31. doi: 10.1007/s100380050032. [DOI] [PubMed] [Google Scholar]
  • 10.Gasser T., Muller-Myhsok B., Wszolek Z. K., et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 1998;18:262–265. doi: 10.1038/ng0398-262. [DOI] [PubMed] [Google Scholar]
  • 11.Waters C. H., Miller C. A. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann. Neurol. 1994;35:59–64. doi: 10.1002/ana.410350110. [DOI] [PubMed] [Google Scholar]
  • 12.Singleton A. B., Farrer M., Johnson J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841. doi: 10.1126/science.1090278. [DOI] [PubMed] [Google Scholar]
  • 13.Leroy E., Boyer R., Auburger G., et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451–452. doi: 10.1038/26652. [DOI] [PubMed] [Google Scholar]
  • 14.Valente E. M., Bentivoglio A. R., Dixon P. H., et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 2001;68:895–900. doi: 10.1086/319522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Valente E. M., Brancati F., Ferraris A., et al. PARK6-linked parkinsonism occurs in several European families. Ann. Neurol. 2002;51:14–18. [PubMed] [Google Scholar]
  • 16.van Duijn C. M., Dekker M. C., Bonifati V., et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet. 2001;69:629–634. doi: 10.1086/322996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bonifati V., Breedveld G. J., Squitieri F., et al. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent data set. Ann. Neurol. 2002;51:253–256. doi: 10.1002/ana.10106. [DOI] [PubMed] [Google Scholar]
  • 18.Funayama M., Hasegawa K., Kowa H., et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann. Neurol. 2002;51:296–301. doi: 10.1002/ana.10113. [DOI] [PubMed] [Google Scholar]
  • 19.Najim al-Din A. S., Wriekat A., Mubaidin A., Dasouki M., Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 1994;89:347–352. doi: 10.1111/j.1600-0404.1994.tb02645.x. [DOI] [PubMed] [Google Scholar]
  • 20.Hampshire D. J., Roberts E., Crow Y., et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J. Med. Genet. 2001;38:680–682. doi: 10.1136/jmg.38.10.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li Y. J., Scott W. K., Hedges D. J., et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 2002;70:985–993. doi: 10.1086/339815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pankratz N., Nichols W. C., Uniacke S. K., et al. Significant linkage of Parkinson disease to chromosome 2q36–37. Am. J. Hum. Genet. 2003;72:1053–1057. doi: 10.1086/374383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Pankratz N., Nichols W. C., Uniacke S. K., et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 2002;71:124–135. doi: 10.1086/341282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Pankratz N., Nichols W. C., Uniacke S. K., et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum. Mol. Genet. 2003;12:2599–2608. doi: 10.1093/hmg/ddg270. [DOI] [PubMed] [Google Scholar]
  • 25.Strauss K. M., Martins L. M., Plun-Favreau H., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 2005;14:2099–2111. doi: 10.1093/hmg/ddi215. [DOI] [PubMed] [Google Scholar]
  • 26.Scott W. K., Nance M. A., Watts R. L., et al. Complete genomic screen in Parkinson disease/evidence for multiple genes. JAMA. 2001;286:2239–2244. doi: 10.1001/jama.286.18.2239. [DOI] [PubMed] [Google Scholar]
  • 27.Bertoli-Avella A. M., Giroud-Benitez J. L., Bonifati V., et al. Suggestive linkage to chromosome 19 in a large Cuban family with late-onset Parkinson's disease. Mov. Disord. 2003;18:1240–1249. doi: 10.1002/mds.10534. [DOI] [PubMed] [Google Scholar]
  • 28.DeStefano A. L., Golbe L. I., Mark M. H., et al. Genome-wide scan for Parkinson's disease/the Gene PD Study. Neurology. 2001;57:1124–1126. doi: 10.1212/wnl.57.6.1124. [DOI] [PubMed] [Google Scholar]
  • 29.Martinez M., Brice A., Vaughan J. R., et al. Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. J. Med. Genet. 2004;41:900–907. doi: 10.1136/jmg.2004.022632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Le W. D., Xu P., Jankovic J., et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 2003;33:85–89. doi: 10.1038/ng1066. [DOI] [PubMed] [Google Scholar]
  • 31.Kitada T., Asakawa S., Hattori N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–608. doi: 10.1038/33416. [DOI] [PubMed] [Google Scholar]
  • 32.Wintermeyer P., Kruger R., Kuhn W., et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport. 2000;11:2079–2082. doi: 10.1097/00001756-200007140-00004. [DOI] [PubMed] [Google Scholar]
  • 33.Harhangi B. S., Farrer M. J., Lincoln S., et al. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci. Lett. 1999;270:1–4. doi: 10.1016/s0304-3940(99)00465-6. [DOI] [PubMed] [Google Scholar]
  • 34.Marx F. P., Holzmann C., Strauss K. M., et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 2003;12:1223–1231. doi: 10.1093/hmg/ddg134. [DOI] [PubMed] [Google Scholar]
  • 35.Valente E. M., Abou-Sleiman P. M., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158–1160. doi: 10.1126/science.1096284. [DOI] [PubMed] [Google Scholar]
  • 36.Martin E. R., Scott W. K., Nance M. A., et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001;286:2245–2250. doi: 10.1001/jama.286.18.2245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Di Fonzo A., Rohe C. F., Ferreira J., et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005;365:412–415. doi: 10.1016/S0140-6736(05)17829-5. [DOI] [PubMed] [Google Scholar]
  • 38.Zhang J., Song Y., Chen H., Fan D. The tau gene haplotype h1 confers a susceptibility to Parkinson's disease. Eur. Neurol. 2005;53:15–21. doi: 10.1159/000082956. [DOI] [PubMed] [Google Scholar]
  • 39.Zheng K., Heydari B., Simon D. K. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch. Neurol. 2003;60:722–725. doi: 10.1001/archneur.60.5.722. [DOI] [PubMed] [Google Scholar]
  • 40.Xu P. Y., Liang R., Jankovic J., et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58:881–884. doi: 10.1212/wnl.58.6.881. [DOI] [PubMed] [Google Scholar]
  • 41.Kahle P. J., Haass C., Kretzschmar H. A., Neumann M. Structure/function of alpha-synuclein in health and disease/rational development of animal models for Parkinson's and related diseases. J. Neurochem. 2002;82:449–457. doi: 10.1046/j.1471-4159.2002.01020.x. [DOI] [PubMed] [Google Scholar]
  • 42.Giasson B. I., Lee V. M. Parkin and the molecular pathways of Parkinson's disease. Neuron. 2001;31:885–888. doi: 10.1016/s0896-6273(01)00439-1. [DOI] [PubMed] [Google Scholar]
  • 43.Shendelman S., Jonason A., Martinat C., Leete T., Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004;2:e362. doi: 10.1371/journal.pbio.0020362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.von Bohlen Und Halbach O. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 2004;318:163–174. doi: 10.1007/s00441-004-0921-7. [DOI] [PubMed] [Google Scholar]
  • 45.Zetterstrom R. H., Williams R., Perlmann T., Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 1996;41:111–120. doi: 10.1016/0169-328x(96)00074-5. [DOI] [PubMed] [Google Scholar]
  • 46.Solano S. M., Miller D. W., Augood S. J., Young A. B., Penney J. B., Jr Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain/genes associated with familial Parkinson's disease. Ann. Neurol. 2000;47:201–210. [PubMed] [Google Scholar]
  • 47.Abeliovich A., Schmitz Y., Farinas I., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239–252. doi: 10.1016/s0896-6273(00)80886-7. [DOI] [PubMed] [Google Scholar]
  • 48.Murray I. J., Medford M. A., Guan H. P., et al. Synphilin in normal human brains and in synucleinopathies/studies with new antibodies. Acta Neuropathol. (Berl) 2003;105:177–184. doi: 10.1007/s00401-002-0629-2. [DOI] [PubMed] [Google Scholar]
  • 49.Xie T., Tong L., Barrett T., et al. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 2002;22:274–283. doi: 10.1523/JNEUROSCI.22-01-00274.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Unoki M., Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene. 2001;20:4457–4465. doi: 10.1038/sj.onc.1204608. [DOI] [PubMed] [Google Scholar]
  • 51.Hauser M. A., Li Y. J., Takeuchi S., et al. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum. Mol. Genet. 2003;12:671–677. [PubMed] [Google Scholar]
  • 52.Barrett T., Xie T., Piao Y., et al. A murine dopamine neuron-specific cDNA library and microarray/increased COX1 expression during methamphetamine neurotoxicity. Neurobiol. Dis. 2001;8:822–833. doi: 10.1006/nbdi.2001.0423. [DOI] [PubMed] [Google Scholar]
  • 53.Stewart G. J., Savioz A., Davies R. W. Sequence analysis of 497 mouse brain ESTs expressed in the substantia nigra. Genomics. 1997;39:147–153. doi: 10.1006/geno.1996.4503. [DOI] [PubMed] [Google Scholar]
  • 54.Thuret S., Bhatt L., O'Leary D. D., Simon H. H. Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta. Mol. Cell. Neurosci. 2004;25:394–405. doi: 10.1016/j.mcn.2003.11.004. [DOI] [PubMed] [Google Scholar]
  • 55.Hicks A. A., Petursson H., Jonsson T., et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 2002;52:549–555. doi: 10.1002/ana.10324. [DOI] [PubMed] [Google Scholar]
  • 56.DeStefano A. L., Lew M. F., Golbe L. I., et al. PARK3 influences age at onset in Parkinson disease/a genome scan in the GenePD study. Am. J. Hum. Genet. 2002;70:1089–1095. doi: 10.1086/339814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Davies R. W., Roberts A. B., Morris A. J., et al. Enhanced access to rare brain cDNAs by prescreening libraries/207 new mouse brain ESTs. Genomics. 1994;24:456–463. doi: 10.1006/geno.1994.1653. [DOI] [PubMed] [Google Scholar]
  • 58.Savioz A., Davies R. W. Discovering genes with localised expression in the mouse brain/cDNAs specific to the substantia nigra. Gene. 1995;154:225–230. doi: 10.1016/0378-1119(94)00864-o. [DOI] [PubMed] [Google Scholar]
  • 59.Alberi L., Sgado P., Simon H. H. Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development. 2004;131:3229–3236. doi: 10.1242/dev.01128. [DOI] [PubMed] [Google Scholar]
  • 60.Simon H. H., Saueressig H., Wurst W., Goulding M. D., O'Leary D. D. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci. 2001;21:3126–3134. doi: 10.1523/JNEUROSCI.21-09-03126.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Venter J. C., Adams M. D., Myers E. W., et al. The sequence of the human genome, Science. 2001;291:1304–51. doi: 10.1126/science.1058040. [DOI] [PubMed] [Google Scholar]
  • 62.Gregory S. G., Sekhon M., Schein J., et al. A physical map of the mouse genome. Nature. 2002;418:743–750. doi: 10.1038/nature00957. [DOI] [PubMed] [Google Scholar]
  • 63.West A. B., Zimprich A., Lockhart P. J., et al. Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur. J. Hum. Genet. 2001;9:659–666. doi: 10.1038/sj.ejhg.5200698. [DOI] [PubMed] [Google Scholar]
  • 64.West A., Farrer M., Petrucelli L., et al. Identification and characterization of the human parkin gene promoter. J. Neurochem. 2001;78:1146–1152. doi: 10.1046/j.1471-4159.2001.00512.x. [DOI] [PubMed] [Google Scholar]
  • 65.Holzmann C., Kruger R., Saecker A. M., et al. Polymorphisms of the alpha-synuclein promoter/expression analyses and association studies in Parkinson's disease. J. Neural. Transm. 2003;110:67–76. doi: 10.1007/s00702-002-0769-5. [DOI] [PubMed] [Google Scholar]
  • 66.Farrer M., Maraganore D. M., Lockhart P., et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 2001;10:1847–1851. doi: 10.1093/hmg/10.17.1847. [DOI] [PubMed] [Google Scholar]
  • 67.Stamatoyannopoulos J. A. The genomics of gene expression. Genomics. 2004;84:449–457. doi: 10.1016/j.ygeno.2004.05.002. [DOI] [PubMed] [Google Scholar]
  • 68.Reveron M. E., Savelieva K. V., Tillerson J. L., et al. l-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology. 2002;23:611–619. doi: 10.1016/s0161-813x(02)00037-2. [DOI] [PubMed] [Google Scholar]
  • 69.Takahashi N., Miner L. L., Sora I., et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA. 1997;94:9938–9943. doi: 10.1073/pnas.94.18.9938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Beal M. F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. NY Acad. Sci. 2003;991:120–131. doi: 10.1111/j.1749-6632.2003.tb07470.x. [DOI] [PubMed] [Google Scholar]
  • 71.Greenamyre J. T., Hastings T. G. Biomedicine: Parkinson's—divergent causes, convergent mechanisms. Science. 2004;304:1120–1122. doi: 10.1126/science.1098966. [DOI] [PubMed] [Google Scholar]
  • 72.Pruitt K. D., Tatusova T., Maglott D. R. NCBI Reference Sequence project: update and current status. Nucleic Acids Res. 2003;31:34–37. doi: 10.1093/nar/gkg111. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from DNA Research: An International Journal for Rapid Publication of Reports on Genes and Genomes are provided here courtesy of Oxford University Press

RESOURCES